Post by TheBridgeon Mar 17, 2025 11:43am
44 Views
Post# 36496461
Significant
SignificantIn an announcement on March 11, 2025, Solvonis Therapeutics PLC announced that they had appointed Dr. Renata Crome as its new independent director, bringing four decades of experience in drug development and regulatory approval.
Her career includes 30 years at pharmaceutical giant Roche, where she played a key role in advancing over 100 therapies from early research to clinical trials.
She is currently a consultant for Novo Nordisk, the maker of Ozempic, and has previously led a UK government-backed Covid-19 treatments programme.
She started her career in academic research, working on piioneering heart transplant programs at St. Thomas's Hospital. After that came the 30 years at Roche, leading the development of several bockbuster drugs, inclluding bevacizumab and obinutuzumab for cancer treatment and Tamiflu for influenza.
In an interview, she said that she can contribute to Solvonis in two ways. First, she has extensive experience as a board member, working on strategy development, execution, and making important decisions to ensure the success of organizations.
Second, she has significant experience in developing treatments for central nervious system(CNS) disorders. She understands the challenges in this field and some of the solutions needed to overcome them. Additionally, she said that she has a strong network of experts in CNS research who she can call upon for advice and support.
She ended by saying, "Firstly, I love the products that Solvonis is developing. They are highly innovative and well-differentiated from other treatments in the same space. The other reason I'm excited to join Solvonis is the strength of the team. It is a highly experienced group of professionals, and it's a privilege to join them."
IMO, this appointment certainly has strengthened Solvonis's position in developing potential products.